Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
.

In addition, at baseline, both atorvastatin treatment groups (5 and 10 mg) showed a trend towards higher plasma levels of PCSK9 compared with the treatment-naïve study population (0 mg atorvastatin), although a direct comparison between these subjects may not be appropriate given the differences in the enrollment criteria with respect to LDL-C levels.

also in 53,322 other papers